ZA202006415B - Tetrabenazine transdermal delivery device - Google Patents

Tetrabenazine transdermal delivery device

Info

Publication number
ZA202006415B
ZA202006415B ZA2020/06415A ZA202006415A ZA202006415B ZA 202006415 B ZA202006415 B ZA 202006415B ZA 2020/06415 A ZA2020/06415 A ZA 2020/06415A ZA 202006415 A ZA202006415 A ZA 202006415A ZA 202006415 B ZA202006415 B ZA 202006415B
Authority
ZA
South Africa
Prior art keywords
tetrabenazine
transdermal delivery
delivery device
adhesive
combination
Prior art date
Application number
ZA2020/06415A
Other languages
English (en)
Inventor
Borsadia Suresh
Patel Kalpana
S Tan Hock
Original Assignee
Shinkei Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shinkei Therapeutics Llc filed Critical Shinkei Therapeutics Llc
Publication of ZA202006415B publication Critical patent/ZA202006415B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2020/06415A 2018-04-25 2020-10-15 Tetrabenazine transdermal delivery device ZA202006415B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862662456P 2018-04-25 2018-04-25
PCT/US2019/028900 WO2019209940A1 (en) 2018-04-25 2019-04-24 Tetrabenazine transdermal delivery device

Publications (1)

Publication Number Publication Date
ZA202006415B true ZA202006415B (en) 2024-04-24

Family

ID=68295781

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/06415A ZA202006415B (en) 2018-04-25 2020-10-15 Tetrabenazine transdermal delivery device

Country Status (15)

Country Link
US (2) US12144899B2 (enExample)
EP (1) EP3784237B1 (enExample)
JP (1) JP7386544B2 (enExample)
KR (1) KR102952482B1 (enExample)
CN (1) CN112165942B (enExample)
AU (1) AU2019261403B2 (enExample)
BR (1) BR112020021700A2 (enExample)
CA (1) CA3097189A1 (enExample)
DK (1) DK3784237T3 (enExample)
ES (1) ES2968827T3 (enExample)
IL (1) IL278185B2 (enExample)
MX (1) MX2020011269A (enExample)
TW (1) TWI832854B (enExample)
WO (1) WO2019209940A1 (enExample)
ZA (1) ZA202006415B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3097189A1 (en) 2018-04-25 2019-10-31 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
US20220362165A1 (en) * 2019-10-22 2022-11-17 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
EP4125902A4 (en) * 2020-03-30 2024-05-22 Shinkei Therapeutics, Inc. TRANSDERMAL ADMINISTRATION OF DEXTROMETHORPHAN
CN116036055A (zh) * 2023-03-16 2023-05-02 上海世领制药有限公司 一种含甲磺酸雷沙吉兰的透皮贴剂及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63313723A (ja) * 1987-06-16 1988-12-21 Nitto Electric Ind Co Ltd 外用貼付剤
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
JP4988080B2 (ja) * 1997-09-05 2012-08-01 日東電工株式会社 経皮吸収型製剤
EP1021204B1 (en) 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US9056060B2 (en) * 2000-09-19 2015-06-16 Henkel Ag & Co. Kgaa Non-reactive adhesive useful in transdermal drug delivery system
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
EP1807033B1 (en) 2004-10-08 2016-07-20 Noven Pharmaceuticals, Inc. Transdermal drug delivery device including an occlusive backing
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
GB0514501D0 (en) 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
WO2011019956A2 (en) 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
CA2972242A1 (en) 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
DE102010024105A1 (de) 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
AU2013243461A1 (en) * 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
EP2872126B1 (en) * 2012-07-16 2017-12-06 Grünenthal GmbH Pharmaceutical patch for transdermal administration of tapentadol
EP2999444A4 (en) * 2013-05-20 2016-10-12 Mylan Inc ADVANCED TRANSDERMAL DOSAGE OF PRAMIPEXOL FOR THE TREATMENT OF NEUROLOGICAL DISEASES
AP2015008920A0 (en) * 2013-06-04 2015-12-31 Lohmann Therapie Syst Lts Transdermal delivery system
EP3398602A1 (en) 2014-01-27 2018-11-07 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CN106061506A (zh) 2014-02-07 2016-10-26 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
NZ725826A (en) 2014-05-06 2023-05-26 Neurocrine Biosciences Inc Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
AR098771A1 (es) * 2014-12-16 2016-06-15 Amarin Tech S A Un dispositivo para la administración transdérmica de rotigotina
AU2016229949B2 (en) 2015-03-06 2021-04-08 Auspex Pharmaceuticals Llc Methods for the treatment of abnormal involuntary movement disorders
KR20240125709A (ko) 2015-06-23 2024-08-19 뉴로크린 바이오사이언시즈 인코퍼레이티드 신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
CN107028916B (zh) * 2016-02-04 2020-05-12 北京泰德制药股份有限公司 含有布比卡因或其药用盐的皮肤外用制剂
ITUB20161016A1 (it) * 2016-02-24 2017-08-24 Emenem Srl Composizioni farmaceutiche o cosmetiche comprendenti un polimero e un promotore di assorbimento per il rilascio controllato di principi attivi
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
CA3051830A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
CN110678181A (zh) 2017-04-01 2020-01-10 阿德普蒂奥制药有限公司 (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
EP3395336A1 (en) * 2017-04-28 2018-10-31 Nitto Denko Corporation Transdermal absorption preparation
EP3664787B1 (en) 2017-07-20 2022-07-20 Neurolixis Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors
GB2565049B (en) 2017-07-27 2020-06-10 Reckitt Benckiser Health Ltd A head assembly of a dermaplaning device
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 特定のvmat2インヒビターを投与するための方法
CA3097189A1 (en) 2018-04-25 2019-10-31 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
US20190374521A1 (en) 2018-06-10 2019-12-12 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion
AU2019287524A1 (en) 2018-06-14 2020-12-24 Neurocrine Biosciences, Inc. VMAT2 inhibitor compounds, compositions, and methods relating thereto

Also Published As

Publication number Publication date
MX2020011269A (es) 2020-12-11
US12144899B2 (en) 2024-11-19
JP7386544B2 (ja) 2023-11-27
DK3784237T3 (da) 2024-01-08
EP3784237A1 (en) 2021-03-03
KR102952482B1 (ko) 2026-04-13
WO2019209940A1 (en) 2019-10-31
US20250144045A1 (en) 2025-05-08
TWI832854B (zh) 2024-02-21
AU2019261403A1 (en) 2020-11-12
EP3784237A4 (en) 2022-02-16
TW202014187A (zh) 2020-04-16
JP2021522240A (ja) 2021-08-30
AU2019261403B2 (en) 2025-05-15
US20210128490A1 (en) 2021-05-06
ES2968827T3 (es) 2024-05-14
IL278185B1 (en) 2024-07-01
IL278185B2 (en) 2024-11-01
CN112165942B (zh) 2024-04-12
CN112165942A (zh) 2021-01-01
IL278185A (enExample) 2020-12-31
EP3784237B1 (en) 2023-11-01
CA3097189A1 (en) 2019-10-31
KR20210005623A (ko) 2021-01-14
BR112020021700A2 (pt) 2021-01-26

Similar Documents

Publication Publication Date Title
ZA202006415B (en) Tetrabenazine transdermal delivery device
PH12018502738A1 (en) Compositions, devices, and methods for the treatment of alcohol use disorder
MX2022010168A (es) Moduladores de calpainas y usos terapeuticos de los mismos.
EP4349735A3 (en) Packages for medical devices
MX2018008190A (es) Sistemas y metodos para la administracion transdermica a largo plazo.
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
MX2017003623A (es) Parche de opipramol.
MX2019005833A (es) Administracion transdermica de agentes grandes.
BR112018008103A2 (pt) análogos de celastrol
DK3706841T3 (da) Kanyleskjoldsfjerner og medikamentafgivelsesindretning, der omfatter kanyleskjoldsfjerneren
MA40473A (fr) Dispositifs d'administration de médicaments à base d'une silicone catalysée par du platine, et leurs procédés d'utilisation
BR112016001781A2 (pt) inibidores de rorc2 e métodos de uso dos mesmos
MX2021006102A (es) Suministro mejorado de agentes grandes.
EP3691641A4 (en) DEXTROMETHORPHANE DEVICE FOR TRANSDERMAL ADMINISTRATION
MX372702B (es) Una composicion antimicrobiana.
FI20165932L (fi) Immunomodulatorisia koostumuksia
AU2017394032A8 (en) Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
EP3389760A4 (en) ELECTROKINETIC TRANSDERMAL AND TRANSMUCOSAL DELIVERY DEVICE
UA122329C2 (uk) Комплекс лікарський засіб-пристрій з вмістом хінаголіду
EP3434314A4 (en) TRANSDERMAL DELIVERY SYSTEM
MX2021015026A (es) Peptido derivado de urlc10 y vacuna que lo contiene.
EP4048268A4 (en) DEVICE FOR TRANSDERMAL ADMINISTRATION OF TETRABENAZINE
MX2018009739A (es) La administración combinada de un agente de penetración y un compuesto que contiene azufre a plantas.
PH12017501563A1 (en) Oligomeric/polymeric silicone fluids for use in transdermal drug delivery systems
EP3766536A4 (en) MEDICATION DELIVERY DEVICE, APPARATUS AND SET